Neves, VeraSilva, Frederico Aires daReal, Sofia CorteCastanho, Miguel A. R. B.2018-04-162018-04-162016Trends in Biotechnology, January 2016, Vol. 34, No. 10167-7799http://hdl.handle.net/10451/32815© 2015 Elsevier Ltd.Recombinant antibodies are an emerging class of therapeutics with substantial promise to treat central nervous system (CNS) diseases such as Alzheimer's, Parkinson's, stroke, and brain cancers. However, poor blood–brain barrier (BBB) permeability hinders the progress of antibody therapies for conditions in which the target is located in the brain. Nonetheless, antibodies can nowa-days be engineered to enhance their therapeutic applications and translocation of the BBB using the natural portals of the brain. This paper reviews advances in the development and engineering of therapeutic BBB-crossing antibodies and their high potential for treatment of CNS disorders.engjournal article10.1016/j.tibtech.2015.10.005